Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy - Observational Long-term Outcome Follow up

Sepsis is a worldwide health threat because of high mortality and the development of long-lasting disabilities, including physical and cognitive impairment and mental disorders, known collectively as post-intensive care syndrome (PICS), which contribute to reduced health-related quality of life (HRQoL) for several years even after successful recovery from the initial acute sepsis state. Sepsis survivors often need a longer period of rehabilitation, consuming more medical and social resources and struggle with financial burdens. In the ReActIF-ICE study, that started enrolling patients in July 2022, up to 142 subjects with severe sepsis are to be enrolled and randomized into a therapy group (receiving the ARTICE treatment (extracorporeal immune cell plasma perfusion) on top of standard care) and control group (standard care only). These subjects were followed up according the ReActIF-ICE study protocol for 90 days. Since there is still a large need for long-term outcome data of sepsis patients, collecting data of the ReActIF-ICE patients over a longer period of time would provide important additional information regarding: 1. General long term clinical and socio-economic outcome of sepsis survivors 2. Long-term outcome details of the ReActIF-ICE patient population 3. The potential long-term medical outcome effects of the additional ARTICE treatment compared to standard treatment alone. 4. The potential long-term health-related quality-of-life effects of ReActIF-ICE patient population 5. The potential long-term health-related quality-of-life effects of the additional ARTICE treatment compared to standard treatment alone. In this long term follow up study, the enrolled subjects shall be followed up beyond 90 days for up to 5 years.